Quantbot Technologies LP Has $1.91 Million Holdings in GSK plc (NYSE:GSK)

Quantbot Technologies LP cut its position in shares of GSK plc (NYSE:GSK) by 69.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 44,556 shares of the pharmaceutical company’s stock after selling 100,156 shares during the quarter. Quantbot Technologies LP’s holdings in GSK were worth $1,910,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Versant Capital Management Inc grew its holdings in GSK by 2,816.7% in the fourth quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock worth $26,000 after purchasing an additional 676 shares during the period. Register Financial Advisors LLC acquired a new stake in GSK in the first quarter worth $31,000. BKM Wealth Management LLC acquired a new stake in GSK in the fourth quarter worth $32,000. Richardson Financial Services Inc. acquired a new position in shares of GSK during the fourth quarter valued at about $40,000. Finally, Newbridge Financial Services Group Inc. acquired a new position in shares of GSK during the first quarter valued at about $49,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. The Goldman Sachs Group assumed coverage on shares of GSK in a report on Thursday, May 30th. They set a “neutral” rating and a $47.00 price objective for the company. UBS Group cut shares of GSK from a “buy” rating to a “neutral” rating in a report on Monday. Berenberg Bank upgraded shares of GSK to a “strong-buy” rating in a report on Thursday, June 20th. Jefferies Financial Group lifted their price objective on shares of GSK from $52.50 to $53.00 and gave the company a “buy” rating in a report on Tuesday, July 2nd. Finally, Citigroup raised shares of GSK to a “strong-buy” rating in a research report on Monday, June 24th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $50.00.

GSK Stock Up 0.7 %

Shares of GSK traded up $0.26 during trading hours on Friday, reaching $39.16. 2,512,036 shares of the stock traded hands, compared to its average volume of 3,584,349. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.15. The stock has a fifty day simple moving average of $41.98 and a 200 day simple moving average of $41.29. GSK plc has a 52 week low of $33.67 and a 52 week high of $45.92. The company has a market cap of $81.16 billion, a price-to-earnings ratio of 14.10, a PEG ratio of 1.17 and a beta of 0.64.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, May 1st. The pharmaceutical company reported $1.09 EPS for the quarter, topping the consensus estimate of $0.94 by $0.15. The business had revenue of $9.34 billion for the quarter, compared to analyst estimates of $8.98 billion. GSK had a net margin of 14.62% and a return on equity of 51.54%. On average, equities analysts forecast that GSK plc will post 4.1 EPS for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, July 11th. Shareholders of record on Friday, May 17th were given a $0.3762 dividend. This is a positive change from GSK’s previous quarterly dividend of $0.36. The ex-dividend date of this dividend was Thursday, May 16th. This represents a $1.50 annualized dividend and a yield of 3.84%. GSK’s payout ratio is currently 53.26%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.